The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
20 December 2023
20 December 2023
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Heart Valve Leaflet Material - Testing Update
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon?), today provides an update on recent developments of the RUA leaflet composite.
The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets.
Testing undertaken by RUA has demonstrated:
· Flex fatigue stability over 400m cycles
· Durability as a heart valve leaflet over 200m cycles
· Remarkable tensile strength properties exceeding both base fabric and polymer
· Similar tensile strength in multiple directions
· Highly flexible allowing improved valve efficiency.
· Narrow crimping profile allowing TAVR benefits
· Retention of ElastEon blood contacting properties such as calcification and thrombogenicity.
· Material very stable with no delamination during testing and high tear resistance.
Aimhigherstill
my reputation is I call on the very bottom of Share price and let people know,
because when good news comes it's hard to buy in good quantities without Going NT.
and they fact Most on AIM like to pay higher price is crazy.
example
I bought #bloe 0.93
now peeps buying at 2p
that's 100% higher than what I paid.
why don't you guys get it......
buy when no one wants them...... sell when all wants in.....
I'm not here for popular votes pal.
see opportunities and take action
GLA
Some saying 50p on the Rns on ADVFN..... won't disagree with them
looking at the $11 billion Market Size and growing fast this could become AIM most valuable companies in the future.
GLA and Dyor before its too late.
The Heart Valves Market in 2023 is US$ 11.55 billion, and is expected to reach US$28.45 billion by 2031 at a CAGR of 11.92%. The heart valves market is a dynamic and rapidly growing industry that plays a crucial role in the field of cardiovascular healthcare.4 Jan 2024
Late print buy just popped up 100k
mms tried hiding this
look how AGL risen on £150k contract announcement to
now RUA Announcement would be in $10m+ minimum because heart valve market is worth multiple of billion dollars
Bill Brown, Chairman of RUA said: "The mutual benefits of this partnership with Corcym are transformational for RUA. Not only does it validate our belief in the product range but it is backed up with Corcym's capacity and capabilities to make the graft range available to heart surgeons globally."
Christian Mazzi , CEO of Corcym added : "Corcym is excited to partner with an innovative company like RUA to commercialise the aortic graft range. Corcym's mission is to help cardiac surgeons treat patients better, today and in the future, and RUA's aortic graft range will be an important addition to the product portfolio we can offer Heart Surgeons worldwide
Looks good
AST rns has all the information
Covid19 made lots of companies go bust,
new company paying $16.5m for what?
assets must be huge......
Why does court wants fxpo to fail???
I mean Fxpo will help rebuild Ukraine when the war is over,
don't know when that's going to happen,
buy court orders are frustrating for fxpo shareholders
Ast not used any Riverfort Service in the last Few years
So that's a good indication,
Plus
#Ast will be with the big boys in the #Usa #helium processing, Purification, Liquification and transportation
Big cake with big slice for #Ast
Let this sink in
However, as a consequence of the above delay, the cash position of the Group has further declined during December 2023. The Company has been unable to meet December 2023 payroll in full and therefore the Company's Directors and senior management have agreed to defer their salaries and fees until such time as the delayed funds are received. The Company has asked certain employees to defer on the same basis, and is pleased that in excess of 67% of Group staff have agreed to full deferral, with a significant additional number agreeing to partial deferral.
Waiting to listen to the interview
this could be the next HE1 in coming months
investors not cotton on to this potential
Ahanda
stop comparing a loss making, cash burning company to a UK corner shop which is in a different league.
SND could do with a placing to give them breathing space for longer life,
but get this..... directors wants to crash sp